Eosinofilia, elevación de proteína C-reactiva y fiebre inducidos por clozapina

Merizalde-Torres, Milton H; García-Sánchez, Nuria G; Barberá-Fons, María A; Plumed-Domingo, José J; Moral-Moral, Pedro.
Actas esp. psiquiatr ; 47(3): 122-126, mayo-jun. 2019. tab
Artículo en Español | IBECS (España) | ID: ibc-185161

Documentos relacionados

  1. Clozapine rechallenge and initiation despite neutropenia- a practical, step-by-step guide.
  2. Escaping the Long Shadow Cast by Agranulocytosis: Reflections on Clozapine Pharmacovigilance Focused on the United Kingdom.
  3. [Underexposed, potential lethal gastrointestinal adverse events associated with clozapine use].
  4. Rates and Reasons for Clozapine Treatment Interruptions: Impact of the Frequency of Hematologic Monitoring and Cardiac Adverse Events.
  5. Continuation of Treatment With Clozapine After an Episode of Neutropenia.
  6. Successful rechallenge with clozapine after treatment associated eosinophilia.
  7. Appendicitis Associated With Clozapine: Analyses Based on a Spontaneous Reporting System Database in Japan.
  8. Clinician Reasons for Stopping Clozapine: A Retrospective Cohort Study.
  9. Monitoring for myocarditis during treatment initiation with clozapine.
  10. Treatment of Clozapine-Associated Sialorrhea: The Role of Benzamide Derivatives.